Zacks Research Analysts Cut Earnings Estimates for Omnicell, Inc. (NASDAQ:OMCL)

Omnicell, Inc. (NASDAQ:OMCL) – Investment analysts at Zacks Research decreased their Q2 2024 earnings per share estimates for shares of Omnicell in a research note issued to investors on Tuesday, April 16th. Zacks Research analyst M. Mondal now anticipates that the company will earn $0.00 per share for the quarter, down from their previous estimate of $0.07. The consensus estimate for Omnicell’s current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Omnicell’s FY2024 earnings at $0.08 EPS, Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.08 EPS, Q4 2025 earnings at $0.12 EPS, FY2025 earnings at $0.29 EPS and Q1 2026 earnings at $0.09 EPS.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 8th. The company reported $0.12 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.22. Omnicell had a positive return on equity of 3.43% and a negative net margin of 1.78%. The company had revenue of $258.85 million during the quarter, compared to the consensus estimate of $256.00 million.

Other equities research analysts also recently issued research reports about the stock. Barclays initiated coverage on shares of Omnicell in a research note on Wednesday, January 3rd. They set an “underweight” rating and a $33.00 price target on the stock. Wells Fargo & Company cut their price target on Omnicell from $28.00 to $26.00 and set an “equal weight” rating on the stock in a research note on Friday, February 9th. Finally, Benchmark lowered their price objective on Omnicell from $42.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, February 9th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $42.20.

Omnicell Trading Up 3.7 %

OMCL opened at $27.25 on Thursday. The firm’s 50 day moving average is $27.72 and its 200-day moving average is $33.01. Omnicell has a 52-week low of $25.69 and a 52-week high of $77.14. The company has a quick ratio of 2.22, a current ratio of 2.52 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $1.25 billion, a P/E ratio of -60.56 and a beta of 0.76.

Hedge Funds Weigh In On Omnicell

A number of hedge funds have recently bought and sold shares of OMCL. Vanguard Group Inc. boosted its holdings in Omnicell by 8.5% in the fourth quarter. Vanguard Group Inc. now owns 5,571,420 shares of the company’s stock worth $209,653,000 after purchasing an additional 434,336 shares during the period. Macquarie Group Ltd. boosted its holdings in shares of Omnicell by 12.5% in the 2nd quarter. Macquarie Group Ltd. now owns 1,218,279 shares of the company’s stock valued at $138,579,000 after buying an additional 135,360 shares during the period. Clearbridge Investments LLC grew its position in shares of Omnicell by 8.9% during the 1st quarter. Clearbridge Investments LLC now owns 1,136,664 shares of the company’s stock valued at $147,187,000 after buying an additional 92,567 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Omnicell by 2.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,067,516 shares of the company’s stock valued at $40,173,000 after buying an additional 21,798 shares during the last quarter. Finally, Pacer Advisors Inc. raised its stake in Omnicell by 321,488.8% during the fourth quarter. Pacer Advisors Inc. now owns 1,058,027 shares of the company’s stock worth $39,814,000 after acquiring an additional 1,057,698 shares during the period. 97.70% of the stock is currently owned by institutional investors and hedge funds.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.